ClinicalTrials.gg
RecruitingNCT07578519Updated Sep 3, 2026

Radiation Treatment of the Prostate That is Specially Adjusted for Each Person

A Phase 2 interventional study of radiotherapy in Prostate Cancer, sponsored by AHS Cancer Control Alberta. Recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AHS Cancer Control Alberta · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · AHS Cancer Control Alberta.

Planned enrollment
6th of 14
50 · median 40
Started
2026
with 1 other
Phase 2
5 of 22
2 open now
Registered
22nd of 22
by date

Among the 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 22nd registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Prostatic Neoplasms by AHS Cancer Control Alberta, or all of them as a file.
02

Study summary

A number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments. This study is designed to determine how tumors inside the prostate respond during these 5 treatments on magnetic resonance imaging (MRI) and use that information to design 2 fraction radiotherapy treatments for prostate cancer.

For these two fraction treatments, the first fraction of radiation will use extra radiation to any nodules in the prostate, and the second fraction of radiation will give extra radiation to the nodule(s) in the prostate based on how those nodules responded to the first fraction of radiation. This idea is a relatively old concept but has not been used in the treatment of cancer yet. This research includes a clinical trial that evaluates whether it is safe to design treatments like this.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Radiotherapy
  • prostate cancer
  • treatment
  • radiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate
  • NCCN risk grouping of intermediate or high risk prostate cancer
  • Patients must be 18 years of age, or older on the day of signing and be willing and able to provide written informed consent/assent
  • Identifiable lesion within the epithelium of the prostate as determined by the treating radiation oncologist
  • Have a prostate imaging reporting and data system (PIRADS) 4 or 5 nodule noted on MRI
  • Have not received prior pelvic radiotherapy
  • greater than 10 years
  • performance status \<3
  • Eligible for SBRT to the prostate

Exclusion criteria

Exclusion Criteria:

  • No identifiable lesion within the prostate on 3T MRI
  • Prior trans-urethral resection of the prostate
  • Non-adenocarcinoma histology
  • Meeting criteria for very high-risk risk or node positive prostate cancer
  • Active inflammatory bowel disease
  • Evidence of disease on CT or bone scan
  • Declined radiotherapy
  • Unlikely to be available for all follow-up appointments
  • Having received androgen deprivation therapy or 5-alpha reductase therapy prior to trial therapy
  • Extensive disease in the posterior prostate or aberrant anatomy that makes the safe delivery of boost irradiation not feasible
  • Unable to understand or sign a study consent form after use of interpreter if required
  • Has a relative to radiotherapy including systemic lupus erythematosus, TNM deficiency or scleroderma
  • Unable to tolerate or ineligible for mpMR imaging
  • Any condition or diagnosis, that could in the opinion of the treating physician or qualified investigator interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Arm 1/Stage 1: 5 weeks

    The first group of 25 patients enrolled will receive 5 fractions of radiotherapy to their prostate with or without radiotherapy to their pelvic lymph nodes and an MRI midway through the treatment to assess the response of disease.

    Radiation: radiotherapy

  • Experimental
    Arm 2/Stage 2: 3 weeks

    The second group of 25 patients enrolled in this study will receive a single fraction of radiation to the prostate +/- pelvis with extra radiation to any nodule(s)/tumors in the prostate identified on MR. They will then have a second MR after 3 weeks and based on that MR a second fraction of radiation to the prostate +/- pelvis will be delivered.

    Radiation: radiotherapy

Interventions

  • Radiationradiotherapy

    External beam radiotherapy via stereotactic body radiotherapy (SBRT).

06

What researchers measure

Primary outcomes

  1. Incidence

    Cumulative incidence of acute common terminology criteria for adverse events (CTCAE) v6.0 ≥ grade 2 genitourinary (GU) toxicity

    Time frame: Baseline 3 weeks (includes treatment period for Arm 1 and 2) 1 month (includes treatment period for Arm 1) 3 months 6 months 2 years

Secondary outcomes

  1. Incidence

    Cumulative incidence of acute CTCAE v6.0 ≥ grade 2 gastrointestinal (GI) toxicity

    Time frame: Baseline 3 weeks 1 month 3 months 6 months 2 years

  2. Incidence

    Cumulative incidence of CTCAE v6.0 ≥ grade 2 GU toxicity at 2 years

    Time frame: 2 years

  3. Incidence

    Cumulative incidence of CTCAE v6.0 ≥ grade 2 GI toxicity at 2 years

    Time frame: 2 years

  4. international index of erectile function (IIEF-5)

    IIEF-5 is a 5-item questionnaire (with a 1- 5 score for each item, 1 being the lowest or worst and 5 the highest/best) used to diagnose erectile disfunction.

    Time frame: Baseline 3 weeks 1 month 3 months 6 months 2 years

  5. expanded prostate cancer index composite (EPIC)

    EPIC is a questionnaire designed to measure Quality of Life issues in patients with Prostate cancer. Overall GU domain is scored from 1 to 5 with 1 being "No problem" and 5 being "Big problem"

    Time frame: 1 month and 2 years post treatment

  6. EPIC GI

    EPIC GI is about bowel habits and abdominal pain and has an overall score of1 - 5 with 1 being "No problem" and 5 being "Big problem"

    Time frame: 1 month and 2 years post treatment

  7. PSA

    Proportion of patients with PSA \<0.4ng/mL at 2 years post treatment

    Time frame: 2 years post treatment

  8. PSA nadir

    Absolute PSA nadir at 2 years post treatment (all therapy)

    Time frame: 2 years post treatment

  9. MRI

    MRI based radiographic response of DIL at on treatment week 3

    Time frame: treatment week 3

  10. MRI response

    MRI based radiographic response at 6 months post treatment

    Time frame: 6 months post treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2031, 58 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 58 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 11, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2032
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578519
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Aug 26, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2032 (estimated)
Last update
Sep 3, 2026

Study contacts

Charlie Kirkby
Contact
Charles.Kirkby@cancercarealberta.ca
403-388-6872

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion